2023
DOI: 10.1016/j.ejmech.2022.114913
|View full text |Cite
|
Sign up to set email alerts
|

Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 40 publications
0
1
0
Order By: Relevance
“… , Additionally, these drugs result in considerable toxicity after long-term use due to off-target interactions with other kinases containing cysteine motifs . There is a growing interest in non-covalent, reversible BTK inhibitors, such as fenebrutinib and vecabrutinib, to overcome drug resistance and minimize off-target effects. , Nonetheless, there remains substantial interest in BTK as a molecular target in medicinal chemistry, with numerous active molecules currently in various stages of drug discovery and development. …”
Section: Introductionmentioning
confidence: 99%
“… , Additionally, these drugs result in considerable toxicity after long-term use due to off-target interactions with other kinases containing cysteine motifs . There is a growing interest in non-covalent, reversible BTK inhibitors, such as fenebrutinib and vecabrutinib, to overcome drug resistance and minimize off-target effects. , Nonetheless, there remains substantial interest in BTK as a molecular target in medicinal chemistry, with numerous active molecules currently in various stages of drug discovery and development. …”
Section: Introductionmentioning
confidence: 99%